Cadrenal names John Sharp interim CFO, board reshuffles after director resigns

Cadrenal Therapeutics, Inc. disclosed in a Form 8-K dated June 25, 2026 that its board had put John P. Sharp into the role of Interim Chief Financial Officer. The move meant Quang X. Pham stepped down from that same interim CFO post.¹ The company said it is now searching for a permanent CFO.¹

Sharp brings a long finance background. He is 61 years old, has more than three decades of experience in financial and business planning, and holds a Senior Director title at Lohman & Associates.¹ He has held CFO posts at multiple biopharmaceutical companies going back to April 2007.¹ His prior roles include serving as CFO of Skye Bioscience since March 31, 2026, and earlier stints at SaNOtize Research and Development Corp from December 2022 to October 2025, PhaseBio Pharmaceuticals from April 2016 to November 11, 2022, HUYA Bioscience International from March 2014 to December 2015, and Ligand Pharmaceuticals from April 2007 to March 2014, according to the filing. He previously worked as an auditor at PricewaterhouseCoopers LLP and holds a business administration degree from San Diego State University, along with an inactive California CPA license.¹

The arrangement runs through a services agreement. Under a Master Services Agreement dated August 21, 2024 with Lohman & Associates, Inc., a new Statement of Work (SOW5) sets billing at $455 per hour for up to 24 hours weekly of Sharp's work as interim CFO.¹

Separately, the filing noted board changes. Steven Zelenkofske, a Class III director, resigned from the board effective June 30, 2026, a move the company said was not tied to any disagreement over its operations, policies, or practices.¹ In response, Glynn Wilson resigned as a Class I director on June 29, 2026 and was reappointed as a Class III director, with a term running to the 2028 annual meeting.¹ Wilson was also reappointed to the Audit and Nominating and Corporate Governance Committees, added to the Compensation Committee, and will keep the standard $35,000 annual director fee for fiscal year 2026, plus periodic equity awards.¹